Estimating the Economic Value Allocation of the Social Surplus Generated by the Utilization of All-Oral Direct-Acting Antivirals for Hepatitis C in the United States, 2015-2019

Conference Reports for NATAP

The International Liver Congress™
EASL - European Association for the
Study of the Liver
June 21-24 2023


Estimating the Economic Value Allocation of the Social Surplus Generated by the Utilization of All-Oral Direct-Acting Antivirals for Hepatitis C in the United States, 2015-2019

	EASL 2023 June 21-23 Vienna Louis P Garrison1,2, Boshen Jiao2,3, Zizi Elsisi1,2, Alon Yehoshua4, Roy Koruth4, Bruce Kreter4, Jens Grueger1,5 1University of Washington, Seattle, WA, USA; 2VeriTech Corporation, Mercer Island, WA, USA; 3Harvard University, T.H. Chan School of Public Health, Cambridge, MA, USA; 4Gilead Sciences, Inc., Foster City, CA, USA; 5Boston Consulting Group, Zurich, Switzerland